6 Results for "

KRas-mediated signaling pathways

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "KRas-mediated signaling pathways" in MCE Product Catalog:

Cat. No.: HY-106381
CAS No.: 12244-57-4
Purity:  ≥98.0%
Target:  

PKC NF-κB TrxR

Research Areas:  

Inflammation/Immunology Cancer

Aurothiomalate sodium acts as an inhibitor of PKCI and TrxR1. Aurothiomalate sodium disrupts the PKCI-Par6-Rac1 signaling pathway, and also inhibits TrxR1 activity, TNFα-induced NF-κB activation, and the expression of pro-inflammatory genes. Aurothiomalate sodium blocks Kras-mediated BASC expansion and lung tumor growth, inhibits anchorage-independent growth and tumorigenicity of lung cancer cells, and suppresses neutrophil chemotaxis, phagocytosis, and leukocyte extravasation. Aurothiomalate sodium can be used in research related to rheumatoid arthritis and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-106381A
Purity:  ≥98.0%
Target:  

PKC TrxR NF-κB

Research Areas:  

Inflammation/Immunology Cancer

Aurothiomalate tetramer sodium is the tetrameric form of Aurothiomalate sodium (HY-106381). Aurothiomalate sodium acts as an inhibitor of PKCI and TrxR1. Aurothiomalate sodium disrupts the PKCI-Par6-Rac1 signaling pathway, and also inhibits TrxR1 activity, TNFα-induced NF-κB activation, and the expression of pro-inflammatory genes. Aurothiomalate sodium blocks Kras-mediated BASC expansion and lung tumor growth, inhibits anchorage-independent growth and tumorigenicity of lung cancer cells, and suppresses neutrophil chemotaxis, phagocytosis, and leukocyte extravasation. Aurothiomalate sodium can be used in research related to rheumatoid arthritis and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-159476
CAS No.: 3030576-80-5
Target:  

Ras

Research Areas:  

Cancer

KRAS inhibitor-26 is a KRas protein inhibitor with activity against dysregulated and mutant KRAS G12C proteins. KRAS inhibitor-26 modulates KRAS-mediated signaling pathways. KRAS inhibitor-26 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-174261
CAS No.: 3082412-00-5
Target:  

Ras

Research Areas:  

Cancer

KRAS-IN-5 (Compound Ex 6) is an orally active and selective inhibitor targeting KRAS mutants (including KRAS G12D, KRAS G12V, KRAS WT) with a GNE IC50 value of 1.3 nM against KRAS G12D. KRAS-IN-5 blocks tumor cell proliferation by inhibiting KRAS-mediated signaling pathways (e.g., reducing ERK phosphorylation). KRAS-IN-5 is promising for research of KRAS mutation-related cancers, such as pancreatic cancer, colorectal cancer, lung cancer .
loading...
    loading...
Cat. No.: HY-W010270A
CAS No.: 74916-57-7
Target:  

PKC NF-κB TrxR

Research Areas:  

Inflammation/Immunology Cancer

Aurothiomalate disodium acts as an inhibitor of PKCI and TrxR1. Aurothiomalate disodium disrupts the PKCI-Par6-Rac1 signaling pathway, and also inhibits TrxR1 activity, TNFα-induced NF-κB activation, and the expression of pro-inflammatory genes. Aurothiomalate disodium blocks Kras-mediated BASC expansion and lung tumor growth, inhibits anchorage-independent growth and tumorigenicity of lung cancer cells, and suppresses neutrophil chemotaxis, phagocytosis, and leukocyte extravasation. Aurothiomalate disodium can be used in research related to rheumatoid arthritis and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-180200
CAS No.: 3032602-44-8
Target:  

Ras ERK

Research Areas:  

Cancer

RNK08954 is an orally active KRASG12D inhibitor with a Kd of 0.0395 nM. RNK08954 selectively binds the inactive GDP-bound KRASG12D form, suppresses downstream KRAS-mediated signaling pathways p-ERK1/2 experssion. RNK08954 inhibits KRASG12D-mutant cell proliferation, induces G0-G1 cell cycle arrest, and inhibits tumor growth in mouse xenograft models. RNK08954 can be used for the research of non-small cell lung cancer, pancreatic ductal adenocarcinoma .
loading...
    loading...